Observational studyCardiorenal medicine2026
Predicting Stroke Incidence Using Estimated Glucose Disposal Rate Index in the Population with Cardiovascular-Kidney-Metabolic Syndrome Stage 0-3 in the Chinese Middle-Aged and Elderly Population.
Observational study in Cardiorenal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardiovascular-kidney-metabolic syndrome: a comprehensive review of pathophysiology, epidemiology, diagnosis, and management.Cardiovascular diabetology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStroke remains a leading cause of death and disability worldwide. Although individuals in cardiovascular-kidney-metabolic (CKM) syndrome stages 0-3 have not yet experienced overt clinical events such as stroke, mounting evidence suggests that these stages often involve subclinical metabolic and vascular injury. Insulin resistance (IR), a hallmark of CKM syndrome, contributes to cerebrovascular injury via mechanisms such as inflammation, oxidative stress, and endothelial dysfunction. The estimated glucose disposal rate (eGDR), a noninvasive index of IR, has shown cardiovascular prognostic value, yet its utility in predicting stroke across early CKM stages remains unclear.
methodsThis study analyzed 4,065 participants from the China Health and Retirement Longitudinal Study (CHARLS) classified as CKM stages 0-3. The eGDR was computed using waist circumference, HbA1c, and hypertension status. K-means clustering identified four longitudinal eGDR changes. Restricted cubic spline (RCS) models were used to determine stage-specific eGDR thresholds for stroke prediction. Cox regression assessed associations between baseline, cumulative, and dynamic eGDR with stroke incidence, while subgroup analyses also employed.
resultsDuring follow-up, 383 incident stroke cases were observed. Lower baseline and cumulative eGDR levels were independently associated with higher stroke risk. Participants with persistently low or sharply declining eGDR group exhibited more than double the stroke risk compared to those with stable high eGDR. The RCS analysis confirmed a linear inverse association between cumulative eGDR and stroke in CKM stages 2-3 and identified optimal thresholds that maximized sensitivity and specificity. Notably, stage 2 presented the lowest threshold (7.41), potentially reflecting a critical tipping point where metabolic burden exceeds vascular compensation.
conclusioneGDR is a clinically relevant predictor of stroke in asymptomatic individuals with CKM syndrome. The application of stage-specific thresholds enhances the precision of early risk stratification and highlights the need for tailored surveillance strategies. These findings suggest the potential value of eGDR monitoring as a practical tool for early risk stratification in metabolically at-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.